Jonsson Comprehensive Cancer Center clinical trial failures

Review 43 stopped clinical trials from Jonsson Comprehensive Cancer Center, including disease areas, phases, and classified stop reasons.

This page groups real ClinicalTrials.gov-derived stopped trial records. The strongest added signal is the stop-reason classification: 2 of these records are likely biological failure signals, while the rest may reflect operational, strategic, regulatory, funding, enrollment, or unclear stop reasons.

Total stopped trials43

Likely biological signals2

Shown below43

Dominant stop reasons

OPERATIONAL: 28
OTHER/UNKNOWN: 13
SAFETY: 2

Notable sponsors

Jonsson Comprehensive Cancer Center: 43

Related phases

Phase I: 21
Phase II: 16
Unknown: 3
Early Phase I: 2
Phase III: 1

Crawlable stopped-trial records

Open Explore

Showing up to 43 representative records from this slice. Each link opens the trial detail page with source attribution and stop-reason context.

NCT04205838: Anakinra in Preventing Severe Chimeric Antigen Receptor T-Cell Related Encephalopathy Syndrome in Patients With Recurrent or Refractory Large B-cell Lymphoma

Phase II Diffuse Large B-Cell Lymphoma, Not Otherwise Specified trial by Jonsson Comprehensive Cancer Center. Stop reason: OPERATIONAL.

slow accrual

NCT05841706: Red Blood Cell Transfusion Thresholds for Improved Quality of Life for Patients Undergoing a Pancreatectomy for Pancreatic Cancer

Early Phase I Resectable Pancreatic Carcinoma trial by Jonsson Comprehensive Cancer Center. Stop reason: OPERATIONAL.

slow accrual

NCT02756130: Birinapant and Carboplatin in Treating Patients and Targeting Recurrent High Grade Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (HGSOC)

Phase I High Grade Fallopian Tube Serous Adenocarcinoma trial by Jonsson Comprehensive Cancer Center. Stop reason: OPERATIONAL.

funding was not secured

NCT05457959: Peptide-Pulsed Dendritic Cell Vaccination in Combination With Nivolumab and Ipilimumab for the Treatment of Recurrent and/or Progressive Diffuse Hemispheric Glioma, H3 G34-mutant

Phase I Diffuse Hemispheric Glioma, H3 G34-Mutant trial by Jonsson Comprehensive Cancer Center. Stop reason: OTHER/UNKNOWN.

Never opened

NCT04375527: Binimetinib and Nivolumab for the Treatment of Locally Advanced Unresectable or Metastatic BRAF V600 Wildtype Melanoma

Phase II Clinical Stage III Cutaneous Melanoma AJCC V8 trial by Jonsson Comprehensive Cancer Center. Stop reason: OPERATIONAL.

poor enrollment

NCT05950113: CART-BCMA/CS1 in Treating Patients With Relapsed or Refractory Multiple Myeloma

Phase I Recurrent Multiple Myeloma trial by Jonsson Comprehensive Cancer Center. Stop reason: OTHER/UNKNOWN.

The study was withdrawn before opening

NCT05720988: Tagraxofusp to Eradicate Measurable Residual Disease in Patients With Acute Myeloid Leukemia

Phase I Acute Myeloid Leukemia trial by Jonsson Comprehensive Cancer Center. Stop reason: OTHER/UNKNOWN.

trial was not opened

NCT01345136: Study of RAD001 for Treatment of NF2-related Vestibular Schwannoma

Phase II Neurofibromatosis Type 2 trial by Jonsson Comprehensive Cancer Center. Stop reason: OPERATIONAL.

slow accrual

NCT03618134: Stereotactic Body Radiation Therapy and Durvalumab With or Without Tremelimumab Before Surgery in Treating Participants With Human Papillomavirus Positive Oropharyngeal Squamous Cell Caner

Phase I Clinical Stage I HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC (American Joint Committee on Cancer) v8 trial by Jonsson Comprehensive Cancer Center. Stop reason: OPERATIONAL.

slow accrual

NCT03904251: CPX-351 and Gemtuzumab Ozogamicin in Treating Patients With Relapsed Acute Myeloid Leukemia

Phase I Acute Myelogenous Leukemia trial by Jonsson Comprehensive Cancer Center. Stop reason: OPERATIONAL.

slow accrual

NCT03240861: Genetically Engineered PBMC and PBSC Expressing NY-ESO-1 TCR After a Myeloablative Conditioning Regimen to Treat Patients With Advanced Cancer

Phase I HLA-A*0201 Positive Cells Present trial by Jonsson Comprehensive Cancer Center. Stop reason: OPERATIONAL.

slow accrual

NCT04280471: Fecal Microbiota Transplantation for the Treatment of Severe Acute Gut Graft-Versus-Host Disease

Phase I Acute Graft Versus Host Disease trial by Jonsson Comprehensive Cancer Center. Stop reason: OTHER/UNKNOWN.

The study was not opened

NCT04185311: Ipilimumab, Nivolumab, and Talimogene Laherparepvec Before Surgery in Treating Participants With Localized, Triple-Negative or Estrogen Receptor Positive, HER2 Negative Breast Cancer-deleted

Phase I Anatomic Stage 0 Breast Cancer AJCC v8 trial by Jonsson Comprehensive Cancer Center. Stop reason: OPERATIONAL.

enrollment

NCT04106362: Radiation Therapy and Cisplatin With or Without Cetuximab in Treating Patients With HPV Positive, KRAS-Variant Stage III-IV Oropharyngeal Squamous Cell Carcinoma

Phase II Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8 trial by Jonsson Comprehensive Cancer Center. Stop reason: OPERATIONAL.

low enrollment

NCT04603365: Pamiparib and Temozolomide for the Treatment of Hereditary Leiomyomatosis and Renal Cell Cancer

Phase II Clear Cell Papillary Renal Neoplasm trial by Jonsson Comprehensive Cancer Center. Stop reason: OPERATIONAL.

enrollment

NCT04777708: BO-112 and Pembrolizumab for the Treatment of PD-1/PD-L1 Refractory Liver Cancer

Early Phase I Advanced Hepatocellular Carcinoma trial by Jonsson Comprehensive Cancer Center. Stop reason: OTHER/UNKNOWN.

Withdrawn by sponsor

NCT03128619: Copanlisib, Letrozole, and Palbociclib in Treating Patients With Hormone Receptor Positive HER2 Negative Stage I-IV Breast Cancer

Phase I Estrogen Receptor Positive trial by Jonsson Comprehensive Cancer Center. Stop reason: OPERATIONAL.

Insufficient accrual

NCT04279561: Effect of Androgen Receptor Signaling Inhibitors on 68Ga-PSMA-11 PET/CT Imaging in Patients With Castration-Resistant Prostate Cancer

Phase I Castration-Resistant Prostate Carcinoma trial by Jonsson Comprehensive Cancer Center. Stop reason: OPERATIONAL.

slow accrual

NCT03745690: Near-Infrared Image Guided Surgical Resection With Indocyanine Green in Treating Patients With Head and Neck Cancer

Phase I Head and Neck Carcinoma trial by Jonsson Comprehensive Cancer Center. Stop reason: OPERATIONAL.

no enrollment

NCT04854044: ONC201 and Radiation Therapy Before Surgery for the Treatment of Recurrent Glioblastoma

Phase I Recurrent Glioblastoma trial by Jonsson Comprehensive Cancer Center. Stop reason: OTHER/UNKNOWN.

The P.I. is not prepared to move forward at this thime

NCT03425461: Anti-SEMA4D Monoclonal Antibody VX15/2503 With Nivolumab or Ipilimumab in Treating Patients With Stage III or IV Melanoma

Phase I Metastatic Melanoma trial by Jonsson Comprehensive Cancer Center. Stop reason: OPERATIONAL.

funding

NCT01532362: Evaluation of Apricoxib (Selective Cyclooxygenase 2 Inhibition) in Modulating T Regulatory Cells of Patients With Early Stage Non-small Cell Lung Cancer

Unknown Non Small Cell Lung Cancer trial by Jonsson Comprehensive Cancer Center. Stop reason: SAFETY.

Drug sponsor stopped drug manufacture due to toxicity issues from other studies

NCT00616642: Rosiglitazone in Treating Patients With Pituitary Tumors

Phase II Brain and Central Nervous System Tumors trial by Jonsson Comprehensive Cancer Center. Stop reason: OPERATIONAL.

low patient recruitment

NCT00880542: Sorafenib and Ifosfamide in Treating Patients With High-Grade Soft Tissue Sarcoma or Bone Sarcoma That Can Be Removed by Surgery

Phase II Sarcoma trial by Jonsson Comprehensive Cancer Center. Stop reason: OPERATIONAL.

The study lost funding.

NCT00612066: Rosiglitazone in Treating Patients With Newly Diagnosed ACTH-Secreting Pituitary Tumor (Cushing Disease)

Phase II Cushing's Disease trial by Jonsson Comprehensive Cancer Center. Stop reason: OPERATIONAL.

Low accrual and funding term ended

NCT00601289: Temozolomide in Treating Patients With Invasive Pituitary Tumors

Phase II Brain and Central Nervous System Tumors trial by Jonsson Comprehensive Cancer Center. Stop reason: OPERATIONAL.

funding term ended

NCT00999557: Bimatoprost Ophthalmic Solution in Increasing Eyebrow and Eyelash Growth in Patients Who Have Undergone Chemotherapy for Breast Cancer and in Healthy Participants

Unknown Alopecia trial by Jonsson Comprehensive Cancer Center. Stop reason: OTHER/UNKNOWN.

Study was never opened

NCT00020774: SCH 66336 With or Without Gemcitabine Followed by Surgery Compared With Surgery Alone in Treating Patients With Primary Liver Cancer

Phase II Liver Cancer trial by Jonsson Comprehensive Cancer Center. Stop reason: OTHER/UNKNOWN.

No stop-reason text available in the compact dataset.

NCT00004878: Donor Lymphocytes to Prevent Graft-Versus-Host Disease in Patients With Chronic Myeloid Leukemia

Phase II Graft Versus Host Disease trial by Jonsson Comprehensive Cancer Center. Stop reason: OTHER/UNKNOWN.

study never opened

NCT00706615: Vaccine Therapy in Treating Women With Previously Treated Metastatic Breast Cancer

Phase I Breast Cancer trial by Jonsson Comprehensive Cancer Center. Stop reason: OPERATIONAL.

no accrual

NCT00093704: Bortezomib and Ganciclovir in Treating Patients With Relapsed or Refractory Epstein Barr Virus-Positive Lymphoma

Phase I Lymphoma trial by Jonsson Comprehensive Cancer Center. Stop reason: OPERATIONAL.

study could not recruit any more patients

NCT00234000: Azacitidine and Arsenic Trioxide in Treating Patients With Myelodysplastic Syndromes

Phase I Leukemia trial by Jonsson Comprehensive Cancer Center. Stop reason: OPERATIONAL.

The study was closed due to poor enrollment

NCT00112749: Infliximab in Treating Cancer-Related Fatigue in Postmenopausal Women Who Have Undergone Treatment for Breast Cancer

Phase II Breast Cancer trial by Jonsson Comprehensive Cancer Center. Stop reason: OPERATIONAL.

Recruitment stopped due to slow accrual and lack of evidence of need for further continuation of protocol in inpatient setting.

NCT00004114: Chemotherapy Plus Peripheral Stem Cell Transplantation in Treating Patients With Advanced Hematologic Cancer

Phase I Leukemia trial by Jonsson Comprehensive Cancer Center. Stop reason: OTHER/UNKNOWN.

Study never opened

NCT01826864: Sargramostim or Hypertonic Saline Before Sentinel Lymph Node Biopsy in Treating Patients With Stage IB-II Melanoma

Phase III Stage IB Melanoma trial by Jonsson Comprehensive Cancer Center. Stop reason: OPERATIONAL.

No participants enrolled

NCT02263898: Intermittent LGX818 and MEK162 in Treating Patients With Metastatic Melanoma Who Have BRAFV600 Mutations

Phase II Recurrent Melanoma trial by Jonsson Comprehensive Cancer Center. Stop reason: OPERATIONAL.

closed without enrollment

NCT03506802: TCR Genetically Engineered PBMC and PBSC After Melphalan Conditioning Regimen in Treating Participants With Relapsed and Refractory Multiple Myeloma

Phase I HLA-A*0201 Positive Cells Present trial by Jonsson Comprehensive Cancer Center. Stop reason: OPERATIONAL.

No Participants Enrolled

NCT02451865: Binimetinib With Docetaxel in Treating Patients With Previously Treated, Stage IV Non-small Cell Lung Cancer

Phase I Recurrent Non-Small Cell Lung Carcinoma trial by Jonsson Comprehensive Cancer Center. Stop reason: OTHER/UNKNOWN.

No stop-reason text available in the compact dataset.

NCT03014804: Autologous Dendritic Cells Pulsed With Tumor Lysate Antigen Vaccine and Nivolumab in Treating Patients With Recurrent Glioblastoma

Phase II Giant Cell Glioblastoma trial by Jonsson Comprehensive Cancer Center. Stop reason: OTHER/UNKNOWN.

Final contract negotiations

NCT02070406: Gene-Modified T Cells, Vaccine Therapy, and Ipilimumab in Treating Patients With Locally Advanced or Metastatic Malignancies

Phase I Unspecified Adult Solid Tumor, Protocol Specific trial by Jonsson Comprehensive Cancer Center. Stop reason: OPERATIONAL.

low accrual

NCT02851381: Compassionate Single Subject Use of FG-3019 (FibroGen) in Locally Advanced, Unresectable Pancreatic Cancer

Unknown Pancreatic Cancer trial by Jonsson Comprehensive Cancer Center. Stop reason: OTHER/UNKNOWN.

The patient passed before treatment could be started

NCT00427427: Delayed Adjuvant Herceptin® Treatment in Patients With HER-2 Positive Breast Cancer

Phase II Breast Cancer trial by Jonsson Comprehensive Cancer Center. Stop reason: OPERATIONAL.

lack of accrual

NCT01029925: Dichloroacetate (DCA) in Patients With Previously Treated Metastatic Breast or Non-Small Cell Lung Cancer (NSCL)

Phase II Metastatic Breast Cancer trial by Jonsson Comprehensive Cancer Center. Stop reason: SAFETY.

DSMB determined, due to higher than expected risk/safety concerns, study should be closed.